Literature DB >> 20621484

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

Harshani R Lawrence1, Aslamuzzaman Kazi, Yunting Luo, Robert Kendig, Yiyu Ge, Sanjula Jain, Kenyon Daniel, Daniel Santiago, Wayne C Guida, Saïd M Sebti.   

Abstract

Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. Focused libraries of novel compounds based on PI-083 chloronaphthoquinone and sulfonamide moieties were synthesized to gain a better understanding of the structure-activity relationship responsible for chymotrypsin-like proteasome inhibitory activity. This led to the demonstration that the chloronaphthoquinone and the sulfonamide moieties are critical for inhibitory activity. The pyridyl group in PI-083 can be replaced with other heterocyclic groups without significant loss of activity. Molecular modeling studies were also performed to explore the detailed interactions of PI-083 and its derivatives with the beta5 and beta6 subunits of the 20S proteasome. The refined model showed an H-bond interaction between the Asp-114 and the sulfonamide moiety of the PI-083 in the beta6 subunit. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621484      PMCID: PMC3530924          DOI: 10.1016/j.bmc.2010.06.038

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  36 in total

1.  Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules.

Authors:  John C Shelley; Anuradha Cholleti; Leah L Frye; Jeremy R Greenwood; Mathew R Timlin; Makoto Uchimaya
Journal:  J Comput Aided Mol Des       Date:  2007-09-27       Impact factor: 3.686

Review 2.  Alternative UPS drug targets upstream the 26S proteasome.

Authors:  Roland Hjerpe; Manuel S Rodríguez
Journal:  Int J Biochem Cell Biol       Date:  2007-12-08       Impact factor: 5.085

Review 3.  Development of proteasome inhibitors in oncology and autoimmune diseases.

Authors:  Mark K Bennett; Christopher J Kirk
Journal:  Curr Opin Drug Discov Devel       Date:  2008-09

Review 4.  The potential of proteasome inhibitors in cancer therapy.

Authors:  Jan Sterz; Ivana von Metzler; Jens-Claus Hahne; Britta Lamottke; Jessica Rademacher; Ulrike Heider; Evangelos Terpos; Orhan Sezer
Journal:  Expert Opin Investig Drugs       Date:  2008-06       Impact factor: 6.206

Review 5.  Proteasome inhibitors: a therapeutic strategy for haematological malignancy.

Authors:  Lisa Judith-Ann Crawford; Brian Walker; Alexandra Elizabeth Irvine
Journal:  Front Biosci       Date:  2008-05-01

6.  Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.

Authors:  Aslamuzzaman Kazi; Harshani Lawrence; Wayne C Guida; Mark L McLaughlin; Gregory M Springett; Norbert Berndt; Richard M L Yip; Saïd M Sebti
Journal:  Cell Cycle       Date:  2009-06-20       Impact factor: 4.534

7.  Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.

Authors:  Michael Groll; Katherine A McArthur; Venkat R Macherla; Rama Rao Manam; Barbara C Potts
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

8.  Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

Authors:  William Fenical; Paul R Jensen; Michael A Palladino; Kin S Lam; G Kenneth Lloyd; Barbara C Potts
Journal:  Bioorg Med Chem       Date:  2008-11-05       Impact factor: 3.641

9.  CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Authors:  Roberto Piva; Bruce Ruggeri; Michael Williams; Giulia Costa; Ilaria Tamagno; Dario Ferrero; Valentina Giai; Marta Coscia; Silvia Peola; Massimo Massaia; Gabriella Pezzoni; Cecilia Allievi; Nicoletta Pescalli; Mara Cassin; Stefano di Giovine; Paola Nicoli; Paola de Feudis; Ivan Strepponi; Ilaria Roato; Riccardo Ferracini; Benedetta Bussolati; Giovanni Camussi; Susan Jones-Bolin; Kathryn Hunter; Hugh Zhao; Antonino Neri; Antonio Palumbo; Celia Berkers; Huib Ovaa; Alberto Bernareggi; Giorgio Inghirami
Journal:  Blood       Date:  2007-12-05       Impact factor: 22.113

10.  The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research.

Authors:  Halina Ostrowska
Journal:  Cell Mol Biol Lett       Date:  2008-02-29       Impact factor: 5.787

View more
  10 in total

Review 1.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

2.  Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.

Authors:  Sevil Ozcan; Aslamuzzaman Kazi; Frank Marsilio; Bin Fang; Wayne C Guida; John Koomen; Harshani R Lawrence; Saïd M Sebti
Journal:  J Med Chem       Date:  2013-05-13       Impact factor: 7.446

3.  Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.

Authors:  Yiyu Ge; Aslamuzzaman Kazi; Frank Marsilio; Yunting Luo; Sanjula Jain; Wesley Brooks; Kenyon G Daniel; Wayne C Guida; Saïd M Sebti; Harshani R Lawrence
Journal:  J Med Chem       Date:  2012-02-14       Impact factor: 7.446

4.  Design, Synthesis, Molecular Docking Analysis and Biological Evaluations of 4-[(Quinolin-4-yl)amino]benzamide Derivatives as Novel Anti-Influenza Virus Agents.

Authors:  Chao Zhang; Yun-Sang Tang; Chu-Ren Meng; Jing Xu; De-Liang Zhang; Jian Wang; Er-Fang Huang; Pang-Chui Shaw; Chun Hu
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

5.  Substituted quinolines as noncovalent proteasome inhibitors.

Authors:  Tanner J McDaniel; Theresa A Lansdell; Amila A Dissanayake; Lauren M Azevedo; Jacob Claes; Aaron L Odom; Jetze J Tepe
Journal:  Bioorg Med Chem       Date:  2016-04-02       Impact factor: 3.641

6.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.

Authors:  Ruda de Luna Almeida Santos; Lin Bai; Pradeep K Singh; Naoka Murakami; Hao Fan; Wenhu Zhan; Yingrong Zhu; Xiuju Jiang; Kaiming Zhang; Jean Pierre Assker; Carl F Nathan; Huilin Li; Jamil Azzi; Gang Lin
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

7.  Synthesis, Characterization and Antibacterial Studies of N-(Benzothiazol-2-yl)-4-chlorobenzenesulphonamide and Its Neodymium(III) and Thallium(III) Complexes.

Authors:  Lawrence Nnamdi Obasi; Uchechukwu Susan Oruma; Ibrahim Abdulrazak Al-Swaidan; Ponnadurai Ramasami; Chigozie Julius Ezeorah; Alfred Ezinna Ochonogor
Journal:  Molecules       Date:  2017-02-22       Impact factor: 4.411

8.  Synthesis, Characterization and In-vitro Evaluation of Novel Naphthoquinone Derivatives and Related Imines: Identification of New Anticancer Leads.

Authors:  Sima Golmakaniyoon; Vahid Reza Askari; Khalil Abnous; Afshin Zarghi; Razieh Ghodsi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

9.  Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors.

Authors:  Mohammad M Al-Sanea; Ahmed Elkamhawy; Sora Paik; Silvia Bua; So Ha Lee; Mohamed A Abdelgawad; Eun Joo Roh; Wagdy M Eldehna; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 10.  Why bortezomib cannot go with 'green'?

Authors:  Li Jia; Feng-Ting Liu
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.